Merck & Co. Stock News

My high-yield dividend watchlist aims for quality stocks at attractive valuations, with a long-term CAGR target of 12%. In December 2025, the watchlist gained 0.03%, outperforming VYM and SPY, though annual performance lagged benchmarks. The Quality portfolio variant has outperformed recently, with all three variants beating benchmarks over the past two months.

Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining traction: Winrevair's rapid ramp to nearly $1B, Capvaxive's $2B+ potential, and subcutaneous Keytruda QLEX extending exclusivity beyond 2028. Financial strength underpins the transition: $17.1B TTM oper...

Merck is rated a buy, with strong earnings growth, rising cash flow, and balance sheet strength supporting a bullish outlook. Keytruda's double-digit growth and margin expansion drive MRK's profits, but future exclusivity loss in 2028 is a material risk. The company trades at a significant discount—13.8x forward PE, the lowest among peers—while showing the best YoY EBITDA growth and a PEG of 1.23.

Merck earns a cautious "Buy" rating due to an intriguing valuation and clear, somewhat manageable uncertainties, especially post-Keytruda expiry in 2028. MRK's heavy reliance on Keytruda poses risk, but Animal Health growth, pipeline depth, and margin strength offer diversification and optionality. Even in conservative scenarios, MRK could deliver ~7% annualized returns, with potential for doub...

Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight loss drugs.

The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.

The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill and its cancer therapy, making them the latest additions to the fast-track program.

Officials pledge ‘massive savings' as companies agree to offer drugs at prices paid in other wealthy countries